Literature for carfilzomib (T01.010, T01.011, T01.012 inhibitor)

(Topics flags: S Structure, T Target, I Inhibitor, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

2020
1. Fricker,L.D.
   Proteasome inhibitor drugs
   Annu Rev Pharmacol Toxicol60, 457-476. PubMed  Europe PubMed DOI  I
2019
2. Besse,A., Besse,L., Kraus,M., Mendez-Lopez,M., Bader,J., Xin,B.T., de Bruin,G., Maurits,E., Overkleeft,H.S. and Driessen,C.
   Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
   Cell Chem Biol26, 340-351. PubMed  Europe PubMed DOI  I
2017
3. Weyburne,E.S., Wilkins,O.M., Sha,Z., Williams,D.A., Pletnev,A.A., de Bruin,G., Overkleeft,H.S., Goldberg,A.L., Cole,M.D. and Kisselev,A.F.
   Inhibition of the proteasome beta2 site sensitizes triple-negative breast cancer cells to beta5 inhibitors and suppresses Nrf1 activation
   Cell Chem Biol24, 218-230. PubMed  Europe PubMed DOI  T  I
2016
4. Csizmadia,V., Hales,P., Tsu,C., Ma,J., Chen,J., Shah,P., Fleming,P., Senn,J.J., Kadambi,V.J., Dick,L. and Wolenski,F.S.
   Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi
   Toxicol Res5, 1619-1628. DOI  I
2015
5. Harshbarger,W., Miller,C., Diedrich,C. and Sacchettini,J.
   Crystal structure of the human 20S proteasome in complex with carfilzomib
   Structure23, 418-424. PubMed  Europe PubMed DOI  S  I
6. Huber,E.M., Heinemeyer,W. and Groll,M.
   Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914
   Structure23, 407-417. PubMed  Europe PubMed DOI  S  I
2014
7. Dasgupta,S., Castro,L.M., Dulman,R., Yang,C., Schmidt,M., Ferro,E.S. and Fricker,L.D.
   Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells
   PLoS ONE9, e103604-e103604. PubMed  Europe PubMed DOI  I
8. Dou,Q.P. and Zonder,J.A.
   Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on Bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system
   Curr Cancer Drug Targets14, 517-536. PubMed  Europe PubMed DOI  I
9. Stein,M.L. and Groll,M.
   Applied techniques for mining natural proteasome inhibitors
   Biochim Biophys Acta1843, 26-38. PubMed  Europe PubMed DOI  I
2013
10. McBride,A. and Ryan,P.Y.
    Proteasome inhibitors in the treatment of multiple myeloma
    Expert Rev Anticancer Ther13, 339-358. PubMed  Europe PubMed DOI  I
2012
11. Kale,A.J. and Moore,B.S.
    Molecular mechanisms of acquired proteasome inhibitor resistance
    J Med Chem55, 10317-10327. PubMed  Europe PubMed DOI  I
12. Kuhn,D.J. and Orlowski,R.Z.
    The immunoproteasome as a target in hematologic malignancies
    Semin Hematol49, 258-262. PubMed  Europe PubMed DOI  I
13. Verbrugge,S.E., Assaraf,Y.G., Dijkmans,B.A., Scheffer,G.L., Al,M., den Uyl,D., Oerlemans,R., Chan,E.T., Kirk,C.J., Peters,G.J., van der Heijden,J.W., de Gruijl,T.D., Scheper,R.J. and Jansen,G.
    Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis
    J Pharmacol Exp Ther341, 174-182. PubMed  Europe PubMed DOI  I
2011
14. Kuhn,D.J., Orlowski,R.Z. and Bjorklund,C.C.
    Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs)
    Curr Cancer Drug Targets11, 285-295. PubMed  Europe PubMed DOI  I
15. Sacco,A., Aujay,M., Morgan,B., Azab,A.K., Maiso,P., Liu,Y., Zhang,Y., Azab,F., Ngo,H.T., Issa,G.C., Quang,P., Roccaro,A.M. and Ghobrial,I.M.
    Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's macroglobulinemia
    Clin Cancer Res17, 1753-1764. PubMed  Europe PubMed DOI  I
2010
16. Dick,L.R. and Fleming,P.E.
    Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
    Drug Discov Today15, 243-249. PubMed  Europe PubMed DOI  V  I
17. Genin,E., Reboud-Ravaux,M. and Vidal,J.
    Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry
    Curr Top Med Chem10, 232-256. PubMed  Europe PubMed DOI  V  I
18. Screen,M., Britton,M., Downey,S.L., Verdoes,M., Voges,M.J., Blom,A.E., Geurink,P.P., Risseeuw,M.D., Florea,B.I., van der Linden,W.A., Pletnev,A.A., Overkleeft,H.S. and Kisselev,A.F.
    Nature of pharmacophore influences active site specificity of proteasome inhibitors
    J Biol Chem285, 40125-40134. PubMed  Europe PubMed DOI  I
2009
19. Parlati,F., Lee,S.J., Aujay,M., Suzuki,E., Levitsky,K., Lorens,J.B., Micklem,D.R., Ruurs,P., Sylvain,C., Lu,Y., Shenk,K.D. and Bennett,M.K.
    Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
    Blood114, 3439-3447. PubMed  Europe PubMed DOI  I